Trial · NCT01382303

Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients

NCT01382303, Phase 4, Completed, Ajou University School of Medicine; results first posted 2017-06-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients. Trials, record NCT01382303. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01382303

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients
NCT number: NCT01382303
Status: Completed
Phases: Phase 4
Enrollment: 174 participants, actual
Lead sponsor: Ajou University School of Medicine
Conditions: Type 2 Diabetes
Interventions: Pentoxifylline, Placebo
First posted: 2011-06-27
Last updated: 2017-06-16
Results first posted: 2017-06-16

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage Change in Proteinuia	baseline and 24 weeks	Changes of urine protein to creatinie ratio from baseline to 24 weeks
Secondary	Percentage Change in Albuminuria	baseline and 24 weeks	Changes of urine albumin to creatinie ratio from baseline to 24 weeks
Secondary	Mean Change of eGFR	baseline and 24 weeks	changes in eGFR from baseline to 24 weeks
Secondary	Mean Change of Creatinine	baseline and 24 weeks	changes serum creatinine from baseline to 24 weeks
Secondary	Mean Change of Fasting Glucose	baseline and 24 weeks	changes serum fasting glucose from baseline to 24 weeks
Secondary	Mean Change of TNF-a	baseline and 24 weeks	changes in TNF-a from baseline to 24 weeks

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Percentage Change in Proteinuia	baseline and 24 weeks	% change from baseline	MEAN
SECONDARY	Percentage Change in Albuminuria	baseline and 24 weeks	% change from baseline	MEAN
SECONDARY	Mean Change of eGFR	baseline and 24 weeks	ml/min per 1.73m2	MEAN
SECONDARY	Mean Change of Creatinine	baseline and 24 weeks	mg/dL	MEAN
SECONDARY	Mean Change of Fasting Glucose	baseline and 24 weeks	mg/dL	MEAN
SECONDARY	Mean Change of TNF-a	baseline and 24 weeks	pg/mL	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Percentage Change in Proteinuia	Pentoxifylline	-23	Inter-Quartile Range -50 to 10	% change from baseline
Percentage Change in Proteinuia	Placebo	-4	Inter-Quartile Range -30 to 40	% change from baseline
Percentage Change in Albuminuria	Pentoxifylline	-10	Inter-Quartile Range -47 to 50	% change from baseline
Percentage Change in Albuminuria	Placebo	-6	Inter-Quartile Range -45 to 41	% change from baseline
Mean Change of eGFR	Pentoxifylline	-1.05	Standard Deviation 18.20	ml/min per 1.73m2
Mean Change of eGFR	Placebo	-3.59	Standard Deviation 14.20	ml/min per 1.73m2
Mean Change of Creatinine	Pentoxifylline	0.03	Standard Deviation 0.16	mg/dL
Mean Change of Creatinine	Placebo	0.04	Standard Deviation 0.15	mg/dL
Mean Change of Fasting Glucose	Pentoxifylline	-10.0	Standard Deviation 38.9	mg/dL
Mean Change of Fasting Glucose	Placebo	8.4	Standard Deviation 37.4	mg/dL

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pentoxifylline	87
Overall Study	STARTED	Placebo	87
Overall Study	COMPLETED	Pentoxifylline	52
Overall Study	COMPLETED	Placebo	70
Overall Study	NOT COMPLETED	Pentoxifylline	35
Overall Study	NOT COMPLETED	Placebo	17

Source ClinicalTrials.gov

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	dyspepsia	Gastrointestinal disorders	Pentoxifylline	7	87
other	dyspepsia	Gastrointestinal disorders	Placebo	1	87
other	nasea	Gastrointestinal disorders	Pentoxifylline	5	87
other	nasea	Gastrointestinal disorders	Placebo	2	87
other	gastric reflux	Gastrointestinal disorders	Pentoxifylline	5	87
other	gastric reflux	Gastrointestinal disorders	Placebo	3	87
other	headache	Vascular disorders	Pentoxifylline	3	87
other	headache	Vascular disorders	Placebo	1	87

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pentoxifylline
Total, all-cause mortality	Placebo
Total, other adverse events	Pentoxifylline	20	87
Total, other adverse events	Placebo	3	87
Total, serious adverse events	Pentoxifylline	0	87
Total, serious adverse events	Placebo	0	87

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
26300986	DERIVED	PubMed
37916745	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Pentoxifylline vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01382303

GET https://conductscience.org/api/trials/v1/NCT01382303/registered

API reference For AI assistants